BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34521801)

  • 1. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
    Bayoumy AB; Mulder CJJ; Loganayagam A; Sanderson JD; Anderson S; Boekema PJ; Derijks LJJ; Ansari AR
    Ther Drug Monit; 2021 Oct; 43(5):617-623. PubMed ID: 34521801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
    Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
    Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
    Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
    Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
    Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
    Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biotransformation of 6-thioguanine in inflammatory bowel disease patients: a comparison of oral and intravenous administration of 6-thioguanine.
    Jharap B; de Boer N; Vos R; Smid K; Zwiers A; Peters G; Mulder C; Wilhelm A; van Bodegraven A
    Br J Pharmacol; 2011 Jun; 163(4):722-31. PubMed ID: 21323897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.
    Fangbin Z; Xiang G; Liang D; Hui L; Xueding W; Baili C; Huichang B; Yinglian X; Peng C; Lizi Z; Yanjun C; Feng X; Minhu C; Min H; Pinjin H
    Medicine (Baltimore); 2016 Apr; 95(15):e3326. PubMed ID: 27082580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease.
    Takatsu N; Matsui T; Murakami Y; Ishihara H; Hisabe T; Nagahama T; Maki S; Beppu T; Takaki Y; Hirai F; Yao K
    J Gastroenterol Hepatol; 2009 Jul; 24(7):1258-64. PubMed ID: 19682195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
    Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
    Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thiopurine Methyltransferase Genetic Polymorphisms and Activity and Metabolic Products of Azathioprine in Patients with Inflammatory Bowel Disease.
    Pashazadeh P; Marjani A; Asadi J; Khoshnia M
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):541-547. PubMed ID: 30451123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between azathioprine dosage, 6-thioguanine nucleotide levels, and therapeutic response in pediatric patients with IBD treated with azathioprine.
    Lee MN; Kang B; Choi SY; Kim MJ; Woo SY; Kim JW; Choe YH; Lee SY
    Inflamm Bowel Dis; 2015 May; 21(5):1054-62. PubMed ID: 25851563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
    Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
    J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.
    Hande S; Wilson-Rich N; Bousvaros A; Zholudev A; Maurer R; Banks P; Makrauer F; Reddy S; Burakoff R; Friedman S
    Inflamm Bowel Dis; 2006 Apr; 12(4):251-7. PubMed ID: 16633046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
    Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
    Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
    Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
    Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB; van Liere ELSA; Simsek M; Warner B; Loganayagam A; Sanderson JD; Anderson S; Nolan J; de Boer NK; Mulder CJJ; Ansari A
    BMC Gastroenterol; 2020 Sep; 20(1):296. PubMed ID: 32917155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
    Lennard L; Van Loon JA; Lilleyman JS; Weinshilboum RM
    Clin Pharmacol Ther; 1987 Jan; 41(1):18-25. PubMed ID: 3467886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R; Chin P; Zhang M; Sies CW; Barclay ML
    Aliment Pharmacol Ther; 2012 May; 35(10):1181-9. PubMed ID: 22486532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
    Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM
    Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
    Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.